Applied DNA Sciences and Smiths Detection Sign MoU to Provide Forensic Testing for SigNature™ DNA
News May 06, 2008
Under the terms of the MOU, Smiths will provide APDN with exclusive use of the Bio-seeq™PLUS platform, centered upon a portable, DNA-verifying device for authentication, anti-counterfeiting and anti-diversion. When used in combination with APDN’s SigNature™ DNA markers, the Bio-seeq™PLUS will provide forensic authentication in the field.
The BioSeeq™ platform was originally developed by Smiths for use by first responders to test for biological agents, where reliability and precision are essential. The Bio-seeq™PLUS is a new version of the system which uses LATE PCR (Linear After The Exponential PCR) a technique for detecting and analyzing small amounts of nucleic acid.
Smiths hold an exclusive license to LATE PCR from Brandeis University. Bio-seeq™PLUS uses a system of disposable reagent cartridges, which allow use in the field with little technical training. The device is a handheld, fully field-portable PCR identifier that is designed to provide results in as little as 20 minutes depending on the type of assay developed. It supports up to 6 independent simultaneous assays.
Dr. James Hayward, APDN President & CEO stated: “The Bio-seeq™PLUS rounds out our three-pronged offering for authenticating originality: nearly instantaneous optical screening, backed up by in-field forensic marker verification, and ultimately supported when required for legal reasons, by in-lab DNA sequencing. We are committed 100% to ensuring that products and documents that have our unique SigNature™ DNA markers can be quickly and forensically authenticated anywhere in the world. More than a deterrent, our SigNature™ marks will catch counterfeiters and enable effective prosecution by manufacturers and Intellectual Property owners.”
New Cell-weighing Technique Helps Predict How Drugs Affect Cancer CellsNews
Researchers at MIT have now shown that they can use a new type of measurement to predict how drugs will affect cancer cells taken from multiple-myeloma patients.READ MORE
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE
Researchers Discover Mutation That Appears to Protect Against Multiple Aspects of Biological AgingNews
The first genetic mutation that appears to protect against multiple aspects of biological aging in humans has been discovered in an extended family of Old Order Amish living in the vicinity of Berne, Indiana, report Northwestern Medicine scientists.READ MORE